First-of-its-Kind triple virus vaccine tested in seniors
NCT ID NCT06604767
Summary
This early-stage study is testing a new vaccine designed to protect against three common respiratory viruses: RSV, human metapneumovirus, and parainfluenza type 3. Researchers are giving different dose combinations to 390 adults aged 60 and older to check if the vaccine is safe and if it triggers a good immune response. The main goal is to see how people tolerate the vaccine and measure antibody levels before and after vaccination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 0360001
Botany, New South Wales, 2019, Australia
-
Investigational Site Number : 0360002
Camberwell, Victoria, 3124, Australia
-
Investigational Site Number : 0360003
Bayswater, Victoria, 3153, Australia
-
Investigational Site Number : 0360004
Miranda, New South Wales, 2228, Australia
-
Investigational Site Number : 0360005
Kanwal, New South Wales, 2259, Australia
-
Investigational Site Number : 0360006
Blacktown, New South Wales, 2148, Australia
-
Investigational Site Number : 0360008
Herston, Queensland, 4006, Australia
-
Investigational Site Number : 0360009
Brookvale, New South Wales, 2100, Australia
Conditions
Explore the condition pages connected to this study.